Dyadic and Fermbox Launch New Animal-Origin-Free Product

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Mar 04 2026

0mins

DYAI+17.79%

Should l Buy DYAI?

Source: Newsfilter

Commercialization Milestone: The launch of Recombinant DNase I (RNase-free) by Dyadic and Fermbox marks the first commercial product following their expanded collaboration in 2025, showcasing Dyadic's accelerated transition from platform development to commercial product expansion, which is expected to drive recurring revenue growth.
Technological Advantage: Produced using Dyadic's high-yield fungal microbial expression platforms and Fermbox's biomanufacturing capabilities, the product is currently available in research grade, with a cGMP-grade version in development to support biopharmaceutical manufacturing and cell and gene therapy applications.
Market Demand Alignment: As a strategically important endonuclease enzyme, Recombinant DNase I is widely used in biological research and molecular diagnostics to effectively clean up residual DNA in samples, ensuring RNA integrity and meeting the market's demand for high-quality biological reagents.
Future Product Pipeline: The collaboration plans to introduce a series of recombinant enzymes and proteins, including recombinant α-lactalbumin and recombinant human FGF-2, targeting high-demand areas such as cell culture media and vaccine manufacturing, further solidifying Dyadic's position in the biotechnology market.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy DYAI?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on DYAI

About DYAI

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Life Sciences Virtual Investor Forum Highlights Available On-Demand

Mar 13 2026Globenewswire

Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.

Life Sciences Virtual Investor Forum Agenda Announced

Mar 10 2026Globenewswire

Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.